Also in other human cancer types, including ductal carcinoma in situ of the breast, pancreatic ductal carcinoma and non-small cell lung, colorectal, oral hypopharynx, prostate and metastatic ovarian cancers, reports do exist that correlate infiltration with CD20+ or CD19+ TAB with poor patient disease outcome, tumor recurrence and/or progression (reviewed in Mohammed et al., 2013; Woo et al., 2014; Dong et al., 2006; Wouters and Nelson, 2018). Here, CD19 is linked to neoplasm.